Gross Profit Comparison: Alnylam Pharmaceuticals, Inc. and Perrigo Company plc Trends

Alnylam vs. Perrigo: A Decade of Gross Profit Trends

__timestampAlnylam Pharmaceuticals, Inc.Perrigo Company plc
Wednesday, January 1, 2014505610001447700000
Thursday, January 1, 2015410970001712400000
Friday, January 1, 2016471590002051800000
Sunday, January 1, 2017765450001979500000
Monday, January 1, 2018731060001831500000
Tuesday, January 1, 20191946880001773300000
Wednesday, January 1, 20204148010001815200000
Friday, January 1, 20217041430001416200000
Saturday, January 1, 20228686010001455400000
Sunday, January 1, 202315178860001680400000
Monday, January 1, 20241924873000
Loading chart...

In pursuit of knowledge

A Tale of Two Companies: Alnylam Pharmaceuticals vs. Perrigo Company

In the ever-evolving landscape of the pharmaceutical industry, Alnylam Pharmaceuticals, Inc. and Perrigo Company plc have showcased intriguing trends in their gross profit margins over the past decade. From 2014 to 2023, Alnylam Pharmaceuticals has experienced a remarkable growth trajectory, with its gross profit surging by over 2,900%, reaching approximately $1.52 billion in 2023. This growth reflects Alnylam's strategic advancements in RNA interference therapeutics.

Conversely, Perrigo Company, a stalwart in the over-the-counter healthcare sector, has maintained a steady gross profit, peaking at around $2.05 billion in 2016. Despite a slight decline, Perrigo's gross profit remains robust, highlighting its resilience in a competitive market. This comparison underscores the dynamic nature of the pharmaceutical industry, where innovation and market adaptation are key to sustained success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025